A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis

Satoshi Takeuchi, Hidehisa Saeki, Shoji Tokunaga, Makoto Sugaya, Hanako Ohmatsu, Yuichiro Tsunemi, Hideshi Torii, Koichiro Nakamura, Tamihiro Kawakami, Yoshinao Soma, Eiichi Gyotoku, Michihiro Hide, Rikako Sasaki, Yukihiro Ohya, Makiko Kido, Masutaka Furue

研究成果: ジャーナルへの寄稿記事

17 引用 (Scopus)

抄録

Background: Pruritis caused by atopic dermatitis (AD) is not always well controlled by topical corticosteroid therapy, but use of tacrolimus often helps to soothe such intractable pruritis in clinical settings. Objective: To determine the anti-pruritic efficacy of topical tacrolimus in treating AD in induction and maintenance therapy. Methods: Prior to the study, patients were randomly allocated into two groups, induction therapy followed by tacrolimus monotherapy maintenance, and induction therapy followed by emollientonly maintenance. In the induction therapy, the patients were allowed to use topical tacrolimus and emollients in addition to a low dose (<10 g/week) of topical steroids. Patients showing relief from pruritis were allowed to proceed to maintenance therapy. Recurrence of pruritis in maintenance therapy was examined as a major endpoint. Results: Two-thirds of patients (44/68; 64.7%) showed relief from pruritis after induction therapy. Pruritis recurred in 23.8% (5/21) of the tacrolimus monotherapy group and in 100% (21/21) of the emollient group during maintenance period, a difference that was statistically significant. Conclusion: Use of topical tacrolimus is effective in controlling pruritis of AD compared to emollient.

元の言語英語
ページ(範囲)144-150
ページ数7
ジャーナルAnnals of Dermatology
24
発行部数2
DOI
出版物ステータス出版済み - 5 1 2012

Fingerprint

Tacrolimus
Atopic Dermatitis
Pruritus
Multicenter Studies
Emollients
Maintenance
Therapeutics
Group Psychotherapy
Adrenal Cortex Hormones
Steroids
Recurrence

All Science Journal Classification (ASJC) codes

  • Dermatology

これを引用

A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis. / Takeuchi, Satoshi; Saeki, Hidehisa; Tokunaga, Shoji; Sugaya, Makoto; Ohmatsu, Hanako; Tsunemi, Yuichiro; Torii, Hideshi; Nakamura, Koichiro; Kawakami, Tamihiro; Soma, Yoshinao; Gyotoku, Eiichi; Hide, Michihiro; Sasaki, Rikako; Ohya, Yukihiro; Kido, Makiko; Furue, Masutaka.

:: Annals of Dermatology, 巻 24, 番号 2, 01.05.2012, p. 144-150.

研究成果: ジャーナルへの寄稿記事

Takeuchi, S, Saeki, H, Tokunaga, S, Sugaya, M, Ohmatsu, H, Tsunemi, Y, Torii, H, Nakamura, K, Kawakami, T, Soma, Y, Gyotoku, E, Hide, M, Sasaki, R, Ohya, Y, Kido, M & Furue, M 2012, 'A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis', Annals of Dermatology, 巻. 24, 番号 2, pp. 144-150. https://doi.org/10.5021/ad.2012.24.2.144
Takeuchi, Satoshi ; Saeki, Hidehisa ; Tokunaga, Shoji ; Sugaya, Makoto ; Ohmatsu, Hanako ; Tsunemi, Yuichiro ; Torii, Hideshi ; Nakamura, Koichiro ; Kawakami, Tamihiro ; Soma, Yoshinao ; Gyotoku, Eiichi ; Hide, Michihiro ; Sasaki, Rikako ; Ohya, Yukihiro ; Kido, Makiko ; Furue, Masutaka. / A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis. :: Annals of Dermatology. 2012 ; 巻 24, 番号 2. pp. 144-150.
@article{b33d34c026b943658451ae61fe988487,
title = "A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis",
abstract = "Background: Pruritis caused by atopic dermatitis (AD) is not always well controlled by topical corticosteroid therapy, but use of tacrolimus often helps to soothe such intractable pruritis in clinical settings. Objective: To determine the anti-pruritic efficacy of topical tacrolimus in treating AD in induction and maintenance therapy. Methods: Prior to the study, patients were randomly allocated into two groups, induction therapy followed by tacrolimus monotherapy maintenance, and induction therapy followed by emollientonly maintenance. In the induction therapy, the patients were allowed to use topical tacrolimus and emollients in addition to a low dose (<10 g/week) of topical steroids. Patients showing relief from pruritis were allowed to proceed to maintenance therapy. Recurrence of pruritis in maintenance therapy was examined as a major endpoint. Results: Two-thirds of patients (44/68; 64.7{\%}) showed relief from pruritis after induction therapy. Pruritis recurred in 23.8{\%} (5/21) of the tacrolimus monotherapy group and in 100{\%} (21/21) of the emollient group during maintenance period, a difference that was statistically significant. Conclusion: Use of topical tacrolimus is effective in controlling pruritis of AD compared to emollient.",
author = "Satoshi Takeuchi and Hidehisa Saeki and Shoji Tokunaga and Makoto Sugaya and Hanako Ohmatsu and Yuichiro Tsunemi and Hideshi Torii and Koichiro Nakamura and Tamihiro Kawakami and Yoshinao Soma and Eiichi Gyotoku and Michihiro Hide and Rikako Sasaki and Yukihiro Ohya and Makiko Kido and Masutaka Furue",
year = "2012",
month = "5",
day = "1",
doi = "10.5021/ad.2012.24.2.144",
language = "English",
volume = "24",
pages = "144--150",
journal = "Annals of Dermatology",
issn = "1013-9087",
publisher = "Korean Dermatological Association",
number = "2",

}

TY - JOUR

T1 - A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis

AU - Takeuchi, Satoshi

AU - Saeki, Hidehisa

AU - Tokunaga, Shoji

AU - Sugaya, Makoto

AU - Ohmatsu, Hanako

AU - Tsunemi, Yuichiro

AU - Torii, Hideshi

AU - Nakamura, Koichiro

AU - Kawakami, Tamihiro

AU - Soma, Yoshinao

AU - Gyotoku, Eiichi

AU - Hide, Michihiro

AU - Sasaki, Rikako

AU - Ohya, Yukihiro

AU - Kido, Makiko

AU - Furue, Masutaka

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Background: Pruritis caused by atopic dermatitis (AD) is not always well controlled by topical corticosteroid therapy, but use of tacrolimus often helps to soothe such intractable pruritis in clinical settings. Objective: To determine the anti-pruritic efficacy of topical tacrolimus in treating AD in induction and maintenance therapy. Methods: Prior to the study, patients were randomly allocated into two groups, induction therapy followed by tacrolimus monotherapy maintenance, and induction therapy followed by emollientonly maintenance. In the induction therapy, the patients were allowed to use topical tacrolimus and emollients in addition to a low dose (<10 g/week) of topical steroids. Patients showing relief from pruritis were allowed to proceed to maintenance therapy. Recurrence of pruritis in maintenance therapy was examined as a major endpoint. Results: Two-thirds of patients (44/68; 64.7%) showed relief from pruritis after induction therapy. Pruritis recurred in 23.8% (5/21) of the tacrolimus monotherapy group and in 100% (21/21) of the emollient group during maintenance period, a difference that was statistically significant. Conclusion: Use of topical tacrolimus is effective in controlling pruritis of AD compared to emollient.

AB - Background: Pruritis caused by atopic dermatitis (AD) is not always well controlled by topical corticosteroid therapy, but use of tacrolimus often helps to soothe such intractable pruritis in clinical settings. Objective: To determine the anti-pruritic efficacy of topical tacrolimus in treating AD in induction and maintenance therapy. Methods: Prior to the study, patients were randomly allocated into two groups, induction therapy followed by tacrolimus monotherapy maintenance, and induction therapy followed by emollientonly maintenance. In the induction therapy, the patients were allowed to use topical tacrolimus and emollients in addition to a low dose (<10 g/week) of topical steroids. Patients showing relief from pruritis were allowed to proceed to maintenance therapy. Recurrence of pruritis in maintenance therapy was examined as a major endpoint. Results: Two-thirds of patients (44/68; 64.7%) showed relief from pruritis after induction therapy. Pruritis recurred in 23.8% (5/21) of the tacrolimus monotherapy group and in 100% (21/21) of the emollient group during maintenance period, a difference that was statistically significant. Conclusion: Use of topical tacrolimus is effective in controlling pruritis of AD compared to emollient.

UR - http://www.scopus.com/inward/record.url?scp=84860643529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860643529&partnerID=8YFLogxK

U2 - 10.5021/ad.2012.24.2.144

DO - 10.5021/ad.2012.24.2.144

M3 - Article

C2 - 22577263

AN - SCOPUS:84860643529

VL - 24

SP - 144

EP - 150

JO - Annals of Dermatology

JF - Annals of Dermatology

SN - 1013-9087

IS - 2

ER -